Merck & Co Inc, founded in 1891 and headquartered in Kenilworth, New Jersey, is a leading global healthcare company dedicated to the research, development, manufacturing, and marketing of prescription medicines, vaccines, biologic therapies, and animal health products. Notable products include the cancer immunotherapy Keytruda, the HPV vaccine Gardasil, and various treatments for cardiovascular and infectious diseases.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Merck began issuing bonds in 1972, establishing a crucial means of raising capital for its extensive R&D initiatives. Among significant issuances, a notable $3 billion bond deal in 2020 was used to finance the company’s research efforts, including projects aimed at combating COVID-19. Currently, Merck’s bond yields are competitive within the pharmaceutical industry, reflecting the company’s solid credit rating and market position. The bonds feature various maturities and fixed rates, appealing to diverse investor strategies. Recent news includes plans for future bond offerings to support ongoing innovations and acquisitions, indicating a proactive approach to capital management.